Patents by Inventor Guanqun Li

Guanqun Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240174648
    Abstract: Provided is a small molecule compound, which is characterized in having the structure represented by the following molecular formula: (I), wherein X1 and X2 are selected from carbon or nitrogen; G1 is a carbocyclic ring or heterocyclic ring having aromaticity; any one or more hydrogen atoms on the ring of G1 are substituted by R1; and R1 is selected from nitrogen-containing groups. The small molecule compound of the present invention can be used as a highly effective and specific JAK kinase inhibitor, specifically a Tyk2 inhibitor; and/or a JAK1 inhibitor, and/or a JAK1/Tyk2 or Tyk2/JAK1, Tyk2/Jak2 dual inhibitor.
    Type: Application
    Filed: October 10, 2020
    Publication date: May 30, 2024
    Inventors: Li Xing, Guanqun Li, Xiaolei Wang, Yuting Cai, Xiang Jiang, Xiang Pan, Wenhao Zhu, Yang Wang, Zengquan Wang
  • Publication number: 20240169916
    Abstract: The pixel driving circuit includes a first switching transistor connected to a first control line, a reference power line, and a first node, a second switching transistor connected to a scan line, a data line, and the first node; a driving transistor connected to the first node, a driving power line, and a second node; a first capacitor connected to the first node and a third node; a second capacitor connected to the third node and a cathode of a organic light-emitting diode; a third switching transistor connected to the third node, the second node, and a second control line; and a fourth switching transistor connected to the second node, an anode of the organic light-emitting diode, and a third control line.
    Type: Application
    Filed: June 12, 2023
    Publication date: May 23, 2024
    Inventors: Tao FAN, Zhenghui YUAN, Yun Wang, Guanqun Li, Baohong Kang
  • Patent number: 11990094
    Abstract: The pixel driving circuit includes a first switching transistor connected to a first control line, a reference power line, and a first node, a second switching transistor connected to a scan line, a data line, and the first node; a driving transistor connected to the first node, a driving power line, and a second node; a first capacitor connected to the first node and a third node; a second capacitor connected to the third node and a cathode of a organic light-emitting diode; a third switching transistor connected to the third node, the second node, and a second control line; and a fourth switching transistor connected to the second node, an anode of the organic light-emitting diode, and a third control line.
    Type: Grant
    Filed: June 12, 2023
    Date of Patent: May 21, 2024
    Assignee: HKC CORPORATION LIMITED
    Inventors: Tao Fan, Zhenghui Yuan, Yun Wang, Guanqun Li, Baohong Kang
  • Publication number: 20240043429
    Abstract: A triazolo pyrazine compound, wherein the triazolo pyrazine compound is a compound as represented by formula (I) as follows, or a stereoisomer, a geometrical isomer, a tautomer, a hydrate, a solvate, and a pharmaceutically acceptable salt or a prodrug thereof, wherein W is selected from a substituted or unsubstituted aryl or heteroaryl, X is C or N, and R is H or any substituent group. When the triazolo pyrazine compound provided by the invention is used as a Tyk2 specific inhibitor, a more targeted drug can be provided for autoimmune inflammatory diseases driven by an IL-23/Th17 axis, and the compound can be used for treating rheumatoid arthritis, psoriasis, ankylosing spondylitis, sicca syndrome, lupus erythematosus, inflammatory bowel disease, Behcet's disease, severe COVID-19 pneumonia and other diseases more safely and effectively.
    Type: Application
    Filed: December 6, 2021
    Publication date: February 8, 2024
    Inventors: Wenkui FANG, Guanqun LI, Yuting CAI, Xiang PAN, Wenhao ZHU, Yang WANG, Zengquan WANG
  • Publication number: 20230406842
    Abstract: The present invention provides a small molecule compound. The small molecule compound is a compound represented by the following formula (I), or a stereoisomer, geometric isomer, tautomer, hydrate, solvate, and pharmaceutically acceptable salt or prodrug thereof, wherein R1 to R5 are each independently selected from C or N; and R is selected from cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl. The small molecule compound of the present invention can inhibit the JAK kinase, and is particularly used as a JAK1/Tyk2 dual inhibitor and a Tyk2 specific inhibitor.
    Type: Application
    Filed: September 24, 2021
    Publication date: December 21, 2023
    Inventors: Wenkui Ken FANG, Guanqun LI, Yuting CAI, Xiang PAN, Wenhao ZHU, Yang WANG, Zengquan WANG
  • Publication number: 20230373933
    Abstract: Provided in the present invention are a small molecule compound, which is the compound represented by formula (I), or a stereoisomer, a geometric isomer, a tautomer, a hydrate, a solvate, and a pharmaceutically acceptable salt or a prodrug thereof, where R1 to R4 are each independently selected from C or N, and wherein R is selected from a cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl. The small molecule compound of the present disclosure can inhibit a JAK kinase, and more particularly is used as a JAK1/Tyk2 dual inhibitor and a Tyk2 specific inhibitor.
    Type: Application
    Filed: September 24, 2021
    Publication date: November 23, 2023
    Inventors: Wenkui Ken FANG, Guanqun LI, Yuting CAI, Xiang PAN, Wenhao ZHU, Yang WANG, Zengquan WANG
  • Publication number: 20220411408
    Abstract: Provided in the present invention is a small molecule compound, which is characterized in that it is a compound or a stereoisomer, geometric isomer, tautomer, racemate, hydrate, solvate, metabolite, and pharmaceutically acceptable salt or prodrug of the compound as represented by the following structural formula: formula (I). The small molecule compound of the present invention is applicable as a highly efficient and specific JAK kinase inhibitor, specifically a Tyk2 inhibitor and/or a JAK1 inhibitor, and/or a JAK1/Tyk2 dual inhibitor.
    Type: Application
    Filed: October 10, 2020
    Publication date: December 29, 2022
    Inventors: Li Xing, Guanqun Li, Xiaolei Wang, Yuting Cai, Xiang Jiang, Xiang Pan, Wenhao Zhu, Yang Wang, Zengquan Wang